

November 10, 2022  
Lian-Sheng Ma, MD  
Editor-in-Chief  
World Journal of Psychiatry

Dear Dr. Ma,

We greatly appreciate all your effort in handing our manuscript entitled "**Tardive sensory syndrome related to lurasidone: a case report**" (Manuscript NO.: 80643, Case Report). We have revised the manuscript substantially, and would like to re-submit it for your consideration for publication in *World Journal of Psychiatry*.

We believe that we have addressed all the concerns of the reviewers, and itemized the changes we made in response. Attached are our responses to the issues raised by the reviewers, along with the revised manuscript with changes in red highlighted font. In addition, the paper has been reviewed by a native English speaking professional; attached find the certificate of English revision. We look forward to hearing from you soon. Thank you very much for your assistance.

Faithfully yours,

Yu Lee, M.D., M.S.

Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung, Taiwan No.123, Ta-Pei Road, Kaohsiung City, Taiwan

Tel: 886-7-7317123 ext 8751; Fax: 886-7-7326817

E-mail: lyu722@cgmh.org.tw

**Reviewer #1:**

The literature review is quite extensive and comprehensive. The purpose is significant. It would be of interest to those who work in this field. Since it is a case report in the conclusions I would be more cautious. Therefore, I would write that further studies are needed to support the hypothesis that Lurasidone may determine the onset of TSS and if other factors may affect.

**Reply:**

Thank you for your comment. We totally agree the reviewer's opinion that the casual inference of Lurasidone and the onset of TSS needs further investigation. We have added the statement in conclusion (page 6) *"However, further studies are needed to support the hypothesis that lurasidone may contribute to the onset of TSS, as well as whether other factors may also contribute."*

The paper has been reviewed by a native English speaking professional; attached find the certificate of English revision.

**Reviewer #2:**

The subject of this manuscript is of value, but there are defects **need to be modified**.

1. Abstract section: .....had taken lurasidone 40-120 mg daily since March 2021.....  
CASE PRESENTATION section: Consequently, the main regimen was shifted to lurasidone 40-120 mg daily in March 2021. The description of drug dosage is unclear.  
Please check and reword clearly.

**Reply:**

We appreciated this valuable suggestion. Based on your recommendation, we have rephrased these sentences as following.

Abstract section (page 2): *"....., initiating a dose of 40 mg daily then up titration to 120*

*mg daily, since March 2021,....."*

CASE PRESENTATION section (page 4): *"As a result, the main regimen was changed to lurasidone, with an initial dose of 40 mg/daily then up titration to 120 mg/daily since March 2021."*

2. CASE PRESENTATION section: A 52-year-old female with no history of medical disease, movement disorders or sensory paresthesia had been diagnosed with schizophrenia since April 2001, and was treated with various antipsychotics, including risperidone 1mg/daily, amisulpride 200mg/daily, quetiapine 200mg/daily, ziprasidone 40mg/daily, and clozapine 125mg/daily, with a duration of a few months, respectively, and olanzapine 10~25mg/daily (June 2013~March 2021), which was fully effective, but was discontinued due to the adverse side effect of weight gain.

**Reply:**

We appreciated this valuable suggestion. We have rephrased the first paragraph of CASE PRESENTATION as following.

CASE PRESENTATION section (page 4): *"A 52-year-old female with no history of medical disease, movement disorders, or sensory paresthesia was diagnosed with schizophrenia in April 2001. She received treatment with various antipsychotics (including risperidone 1 mg/daily, amisulpride 200 mg/daily, quetiapine 200 mg/daily, ziprasidone 40 mg/daily, and clozapine 125 mg/daily), each with a duration of a few months. Subsequently, this patient received a regimen of olanzapine (10~25 mg daily, June 2013~March 2021), which was fully effective but discontinued due to the adverse side effect of weight gain."*

Finally, the paper has been reviewed by a native English speaking professional; attached find the certificate of English revision.

**Reviewer #3:**

The manuscript is well written and interesting. However, in your paper, you should present the Tardive sensory syndrome on your therapy switching from lurasidone to quetiapine, such as videos.

**Reply:**

Thank you for your comment! We provided a video as a supplementary material to present the patient's statement of mandibular sensory paresthesia and pain, without oral infection or other lesions.

The paper has been reviewed by a native English speaking professional; attached find the certificate of English revision.

**Reviewer #4:**

Great case, nicely described with potential mechanisms about the neuro chemical intereactions.

**Reply:**

Thank you for your comment. The paper has been reviewed by a native English speaking professional; attached find the certificate of English revision. We greatly appreciate all your efforts and your helpful suggestions in reviewing this manuscript.